Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO						DBARECKIPPATO 31	JAN 2005
					Application Number	TBA	And know
THEODAY ARYON DYOCK OCKIDE					Filing Date	January 31, 2005	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				CLUSUKE	First Named Inventor	Ferenc Buzsaky	
				PLICANT	Art Unit	TDA 1615	
(Use as many sheets as necessary)					Examiner Name	TBA-HASAN S. AHME	>
Sheet		1 _	of	2	Attorney Docket Number	1103326-0786	

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.1	Document Number Number-Kind Code ^{2 ((/ Enough)}	Publication Date MM-DD-YYYY	Name of Patentee Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages/Figures Appear
40		US-4,784,858	11-15-1988	Ventouras	
7		US-5,292,522	03-08-1994	Petereit et al.	
7		US-5,478,573	12-26-1995	Eichel et al.	
(a)		US-5,871,776	02-16-1999	Mehta	
	{				

		FOREIGN	PATENT DOC	UMENTS			
Examiner Initials	Cite No.	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear		
40		WO 02/058677-A1	08-01-2002	Hölzer et al.		Π	
Ja		WO 03/051340-A1	06-26-2003	Hjartstam et al.			
	_l	NON PATENT				!	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETT serial, symposium, catalog, etc.), date, pa	ERS), title of the articlage(s), volume-issue nu	e (when appropriate), title of t imber(s), publisher, city and/o	r country where published.	Т	
JHL.	<u>L</u> .	LIN et al., AAPS Pharmasci., volume 3	(2), article 14, 200	1, pages 1-12.			
\uparrow		WESSELING et al., European Journal of pages 73-78.	of Pharmaceutics an	d Biopharmaceutics, vol	ume 47, no. 1, 1999,		
		MATHIR et al., J. Microencapsulation,	volume 14, no. 6, 1	997, pages 743-751.			
		PETEREIT et al., European Journal of F pages 15-25.	Pharmaceutics and I	Biopharmaceuties, volum	e 47, no. 1, 1999,		
		PETEREIT et al., European Journal of I pages 219-228.	Pharmaceutics and l	Biopharmaceutics, vol. 4	I, no. 4, August I, 1995,		
		RAGNARSSON et al., Drug Develop. a	and Ind. Pharmacy,	vol. 13, pages 1495-1509	(1987).		
		SANDBERG et al., European Journal o	f Clin. Pharmacol.,	vol. 33 (1988), pages S3-	-S7 and S9-S14.		
		RAGNARSSON et al., International Jou	umal of Pharmaceu	tics, vol. 79, pages 223-2	32 (1992).		
V	SANDBERG et al., International Journal of Pharmaceutics, vol. 68, pages 167-177 (1991).						
-Ha		SANDBERG et al., Pharmaceutical Res	earch, vol. 10, page	es 28-34 (1993).			
	_						
				· · · · · · · · · · · · · · · · · · ·			
		1 A A	·	15.76.11	10 Turne 42 =	_	
Examiner Si	gnature		,	Date Considered	12 SAMMARY COD		

EXAMINER: Initial if reference considered, whether or not citation is so conformance with MPEP 609. Draw line through citation if not in conformance and not considered, because copy of this florm with near communication to applicant. 'Applicant's unique citation designation member (optional). 'See Kinds Codes of USFTO Patent Documents as www.nespect.gov or MPEP 901.04. 'Exter Office that issued the document, by the two-letter code (WIPO Standard ST.1.9). 'Per Jupanese patent documents, the indication of the year of the reign of the Emporer must precede the serial number of the patent document. Yind of societies of the patent document is unique as the application is smalled. This collection of information is required by 37 CPR 1.79 and 1.98. The information is required by the public which is to file (and by the USFTO to proceed) application. Confidentiality is powered by 35 US.C. 122 and 37 CPR 1.14. This collection is estimated to take 2 hours to complete, including gathering, prograing, and enhantising the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form moder suggestion. Confidentiality is provided by the season of the patent and officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORM TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10/523553

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

0.1 1/2 16 6 1440/07/0				Edmariting/exactipto 5 Jan and			
Substitute for form 1449/PTO				Application Number	TBA	₩~	
	TATEODRA A TOTOR	TDICCI	OCLUBE	Filing Date	January 31, 2005	1	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				First Named Inventor	Ferenc Buzsaky	7	
				Art Unit	TBA-1615		
	(Use as many she		- -	Examiner Name	IBA HASINS SHIPED		
Sheet	2	of	2	Attorney Docket Number	1103326-0786		

xaminer nitials	Cite No.	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
110		SANDBERG et al., Drug Invest., vol. 6, pages 320-329 (1993).	
4		AMIGHI AND MOËS, S.T.P. Pharma Sci., vol. 7(2), pages 141-147 (1997).	
		BODMEIER AND PAERATAKUL, Pharm. Res., vol. 11(6), pages 882-888 (1994).	
		OZTURK et al., J. Controlled Release, vol. 14, pages 203-213 (1990).	
		GOODHART et al., Pharmaceutical Tech., April 1984, pages 64-71.	
		BODMEIER AND PAERATAKUL, International Journal of Pharmaceutics, vol. 152, pages 17-26 (1997).	
V		BODMEIER AND PAERATAKUL, Drug Develop. and Ind. Pharmacy, vol. 20(9), pages 1517-1533 (1994).	
310		SPERLING et al., Journal of Applied Polymer Science, vol. 14, page 73-78 (1970).	
			
		1100	
Examiner Sig	nature	Date Considered & Sanuary 2008	Т

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next continuation to applicant a naiper citation designation number (optional). See Kinds Codes of USFTO Patent Documents a NFW REPRO, pay or MPEP 901.08. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent document, the indication of the year of the rings of the Emperor must precede the serial number of the patent document. Wind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. "Applicant is to place a check must be over if faults the paragrape Translation is required by 31 U.S.C. 122 and 37 CFR 1.14. This collection is in information is required by 40 uses the complete the formation is required to obtain or retain a benefit of by the public which is to file (and by the USFTO to process) as application. Confidentiality is governed by 33 U.S.C. 122 and 37 CFR 1.14. This collection is calmated to take 2 hours to complete, including suffering, preparing, and submitting the completed application form to the USFTO. Time will vary depending once the distribution and the complete the formation of file formation Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORM TO THIS ADDRESS. SEND TO: Commissioner for Patenta, P.O. Box 1450, Alexandria, VA 22313-1450.